Robert W. Garrett1, Andrew L. Wentland1, Arjang Djamali2, Anna Haemel3, Garima Agrawal1, Edwin Stanley4, Elizabeth A. Sadowski1
1Department of Radiology, University of Wisconsin, Madison, WI, USA; 2Department of Nephrology, University of Wisconsin, Madison, WI, USA; 3Department of Dermatology, University of Wisconsin, Madison, WI, USA; 4Department of Surgery, University of Wisconsin, Madison, WI, USA
The purpose of this study was to assess the impact of clinical guidelines developed at our institution to reduce the risk of nephrogenic systemic fibrosis (NSF)which included substituting gadobenate dimeglumine for gadodiamide in high risk patients. Retrospective analysis identified a group of high risk inpatients who received gadobenate dimeglumine over a one year period following NSF screening program implementation. This was compared with a similar population of high risk patients who received gadodiamide during the year prior to screening program implementation. There was a statistically significant reduction in NSF cases following implementation of these guidelines.